Want to see CANF full AI Analyst Report?
CANF Stock Chart & Stats
$3.19
-$0.04(-1.25%)
At close: 4:00 PM EDT
$3.19
-$0.04(-1.25%)
Day’s Range― - ―
52-Week Range$2.56 - $13.78
Previous Close$3.26
Volume20.73K
Average Volume (3M)258.05K
Market Cap
$7.46M
Enterprise Value-$3.23
Total Cash (Recent Filing)$8.54M
Total Debt (Recent Filing)$71.00K
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 27, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)88.41
Price to Sales (P/S)1211.03
P/FCF Ratio-54.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.00Price Target Upside150.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Patent Protection For NamodenosonExpanded patent allowance in Australia adds durable exclusivity for Namodenoson in oncology, strengthening the company’s IP moat across key markets. This supports future commercialization and partnering, improving bargaining power for licensing deals and reducing generic/competitive risk over the medium term.
Diversified Late-stage Pipeline Across IndicationsMultiple late-stage programs across oncology, liver and inflammatory diseases spread clinical and commercial risk. Having pivotal Phase III and Phase IIb trials advances several potential launch paths, increases partnering/licensing options, and creates multiple durable value catalysts rather than a single binary outcome.
Low Leverage And Conservative Balance SheetMinimal debt lowers default and refinancing risk during prolonged drug development cycles. A conservative capital structure preserves strategic optionality to raise funds or negotiate deals without immediate solvency pressure, supporting the company’s ability to continue clinical programs over the medium term.
Bears Say
Persistent Negative Cash Flow And BurnConsistently negative operating and free cash flow indicate the business cannot self-fund development. Despite partial FCF improvement in 2024–2025, ongoing cash burn raises dilution and financing risk, forcing reliance on external capital which can constrain R&D pacing and strategic flexibility.
Small And Declining Revenue With Large LossesFalling revenue and widened losses reduce the firm’s ability to fund trials organically or sustain commercial build-out. Persistent negative profitability over multiple years makes the business outcome highly dependent on clinical readouts and licensing milestones rather than stable operating cash generation.
Revenue Reliance On Milestone/licensing PaymentsMaterial near-term revenue comes from licensing and milestone receipts, which are lumpy and binary. Dependence on partner deals creates revenue volatility and links growth to third-party commercialization choices, limiting predictable, internally generated revenue streams and increasing strategic execution risk.
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $2.56 and its highest was $13.78 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $7.46M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Aug 27, 2026 which is in 13 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Mar 26, 2026. The company reported -$5.97 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$5.83.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.33.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 2,142,546 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$5.97 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 1.858%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
CANF Stock 12 Month Forecast
Average Price Target
$8.00
▲(150.78% Upside)